Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 28 | 2.790 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2026 | 83 | 1.490 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 23 | 1.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 27 | 1.310 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2025 | 22 | 1.140 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 43 | 1.020 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 11 | 0.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 414 | 0.820 |
Why?
|
| Databases, Factual | 2 | 2022 | 265 | 0.810 |
Why?
|
| Leukemia, B-Cell | 1 | 2021 | 3 | 0.700 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 19 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 3 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 44 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 68 | 0.630 |
Why?
|
| Alkylating Agents | 1 | 2019 | 7 | 0.610 |
Why?
|
| Myeloproliferative Disorders | 1 | 2019 | 12 | 0.600 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 21 | 0.600 |
Why?
|
| Humans | 22 | 2026 | 28581 | 0.510 |
Why?
|
| Cyclophosphamide | 3 | 2025 | 41 | 0.390 |
Why?
|
| Vincristine | 2 | 2021 | 9 | 0.340 |
Why?
|
| Prednisone | 2 | 2021 | 53 | 0.340 |
Why?
|
| Aged | 5 | 2025 | 5525 | 0.340 |
Why?
|
| Doxorubicin | 2 | 2021 | 77 | 0.330 |
Why?
|
| Graft vs Host Disease | 2 | 2026 | 31 | 0.300 |
Why?
|
| Young Adult | 3 | 2025 | 2804 | 0.270 |
Why?
|
| Carbohydrate Metabolism | 1 | 2026 | 30 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 1 | 2026 | 55 | 0.240 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 302 | 0.230 |
Why?
|
| Donor Selection | 1 | 2025 | 3 | 0.230 |
Why?
|
| Feces | 1 | 2026 | 114 | 0.230 |
Why?
|
| Cytomegalovirus | 1 | 2025 | 22 | 0.230 |
Why?
|
| Tissue Donors | 1 | 2025 | 24 | 0.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2025 | 44 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 36 | 0.220 |
Why?
|
| Incidence | 3 | 2026 | 568 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 83 | 0.210 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2026 | 135 | 0.210 |
Why?
|
| United States | 3 | 2025 | 2201 | 0.210 |
Why?
|
| Bacteria | 1 | 2026 | 286 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2026 | 2612 | 0.200 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 100 | 0.200 |
Why?
|
| SEER Program | 1 | 2023 | 47 | 0.200 |
Why?
|
| Pericarditis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 75 | 0.190 |
Why?
|
| Recurrence | 2 | 2020 | 325 | 0.190 |
Why?
|
| Normal Distribution | 1 | 2022 | 7 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 98 | 0.180 |
Why?
|
| Adolescent | 3 | 2025 | 3165 | 0.180 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 38 | 0.180 |
Why?
|
| Prognosis | 1 | 2023 | 807 | 0.180 |
Why?
|
| Rituximab | 1 | 2021 | 64 | 0.180 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 13 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 126 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2022 | 134 | 0.170 |
Why?
|
| Adult | 5 | 2026 | 7922 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2020 | 8 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 38 | 0.170 |
Why?
|
| Etoposide | 1 | 2020 | 19 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 66 | 0.160 |
Why?
|
| Heart | 1 | 2021 | 224 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 12 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2020 | 46 | 0.160 |
Why?
|
| Middle Aged | 4 | 2026 | 7310 | 0.160 |
Why?
|
| Pheochromocytoma | 1 | 2019 | 9 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cohort Studies | 1 | 2021 | 893 | 0.150 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 285 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 402 | 0.150 |
Why?
|
| Survivors | 1 | 2019 | 40 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 137 | 0.150 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 2045 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2402 | 0.130 |
Why?
|
| Female | 5 | 2026 | 15471 | 0.120 |
Why?
|
| Male | 4 | 2026 | 13771 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 48 | 0.120 |
Why?
|
| Bibliometrics | 1 | 2015 | 20 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 357 | 0.110 |
Why?
|
| Smoking | 1 | 2018 | 476 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2015 | 98 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 857 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 373 | 0.090 |
Why?
|
| Age Factors | 2 | 2025 | 734 | 0.080 |
Why?
|
| Animals | 1 | 2021 | 10580 | 0.060 |
Why?
|
| Metagenomics | 1 | 2026 | 57 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2025 | 93 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 49 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cladribine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Pharmacovigilance | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 8 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 8 | 0.050 |
Why?
|
| Triazines | 1 | 2022 | 11 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 52 | 0.050 |
Why?
|
| Comorbidity | 1 | 2023 | 259 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 45 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 32 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 240 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2022 | 73 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 22 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 42 | 0.050 |
Why?
|
| Hospitalization | 1 | 2023 | 199 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2021 | 63 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 209 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 63 | 0.040 |
Why?
|
| Catecholamines | 1 | 2019 | 18 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 90 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 186 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 285 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 160 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 236 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 170 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 431 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 467 | 0.030 |
Why?
|
| Middle East | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 864 | 0.030 |
Why?
|